JP2001519787A - 膀胱内ドラッグデリバリーシステム - Google Patents
膀胱内ドラッグデリバリーシステムInfo
- Publication number
- JP2001519787A JP2001519787A JP54197098A JP54197098A JP2001519787A JP 2001519787 A JP2001519787 A JP 2001519787A JP 54197098 A JP54197098 A JP 54197098A JP 54197098 A JP54197098 A JP 54197098A JP 2001519787 A JP2001519787 A JP 2001519787A
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- active ingredient
- bladder
- preparation
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.医薬活性成分及び生分解性の医薬的に許容される担体を含有する、尿道を通 して膀胱に設置するための生分解性持続性放出製剤であって、該担体が膀胱内 に該活性成分を持続的に放出でき、かつ生分解後に尿管を通って排出できるも のである、上記生分解性持続性放出製剤。 2.該製剤が、25℃で約1.005未満の比重を有する、請求項1記載の製剤。 3.活性成分が、オキシブチニン、ドクソルビシン、イミプラミン、ジシクロミ ン、デスモプレシン、エストロゲン、テロヂリン、プロパンテリン、ドクセピ ン及びフラボキセートからなる群から選ばれる、請求項1記載の製剤。 4.活性成分が、オキシブチニンである、請求項1記載の製剤。 5.さらに、膀胱の内皮に接着可能な粘液性表面を含む請求項1記載の製剤。 6.該製剤がパッチを含む請求項5記載の製剤。 7.該製剤がタブレットを含む請求項5記載の製剤。 8.挿入のために伸びていない形態で尿管を通過可能で、伸びた形態で膀胱に保 持可能な延伸可能なフィラメントを含む請求項1記載の製剤。 9.フィラメントがコイルを含む請求項8記載の製剤。 10.フィラメントがフープを含む請求項8記載の製剤。 11.フィラメントがランダムコイルを含む請求項9記載の製剤。 12.フィラメントが、球の孔に合致する球状のケージを含む請求項8記載の製剤 。 13.フィラメントが、その末端から徐々に分解可能である請求項8記載の製剤。 14.フィラメントが、別々のセグメントに徐々に分解可能である請求項8記載の 製剤。 15.フィラメントが、多孔質連続気泡フォームを形成する請求項8記載の製剤。 16.さらに、該活性成分を制御可能に放出できるリザーバーを含む請求項1記載 の製剤。 17.ゲルを含む請求項1記載の製剤。 18.ゲルが、膀胱内の尿と接触して形成される請求項17記載の製剤。 19.ゲルが粘液接着性である請求項17記載の製剤。 20.ゲルが尿よりも小さい比重を有する請求項18記載の製剤。 21.該活性成分がゲル内に分散された担体内にある請求項17記載の製剤。 22.該担体が、微小球体、リポソーム又はエマルションを含む請求項21記載の製 剤。 23.担体が完全に分解する前に、該活性成分が担体から放出される請求項1記載 の製剤。 24.担体が生分解するに従って、該活性成分が制御可能に放出される請求項1記 載の製剤。 25.該活性成分が、間質性膀胱炎の治療用である請求項1記載の製剤。 26.該活性成分が、癌の治療用である請求項1記載の製剤。 27.該活性成分が、失禁の治療用である請求項1記載の製剤。 28.該活性成分が、炎症の治療用である請求項1記載の製剤。 29.該活性成分が、感染の治療用である請求項1記載の製剤。 30.さらに、該活性成分の放出速度を変更する放出速度調整剤を含有する請求項 1記載の製剤。 31.持続した放出の放出速度が、担体に対する該活性成分の化学親和性により調 整される請求項1記載の製剤。 32.放出速度調整剤が、担体に含まれている請求項30記載の製剤。 33.放出速度調整剤が、飽和脂肪酸、不飽和脂肪酸、コール酸、ジアシルホスホ ン酸、リン脂質、クエン酸のエステル、安息香酸、置換安息香酸、置換フェノ ール、イオン交換ポリマー、メタクリレート−メタクリル酸コポリマー、レシ チン、硝酸アルキルエステル及びアルキルセルロースからなる群から選ばれる 請求項30記載の製剤。 34.前記調整剤が不飽和脂肪酸を含む請求項33記載の調製物。 35.前記脂肪酸がオレイン酸を含む請求項34記載の調製物。 36.前記ゲルが相転移成分及びレオロジー調整成分を含む請求項18記載の調製 物。 37.前記相転移成分が、ゲランガム、アルジネート、カルボキシメチルセルロー ス、ポリアクリル酸及びカルボキシメチルキトサンからなる群から選択される 請求項36記載の調製物。 38.前記固相転移成分がゲランガムを含む請求項37記載の調製物。 39.前記レオロジー調整成分が、ポリエチレンオキシド、ポリビニルポリプロピ レン、デキストラン、デキストロース、ポリエチレンオキシド/ポリビニルポ リプロピレンコポリマー、ヒアルロン酸、ヒドロキシエチルセルロース、ポリ アクリルアミド、ポリビニルアルコール、キトサン及びゼラチンからなる群か ら選択される請求項36記載の調製物。 40.前記レオロジー調整成分がポリエチレンオキシドを含む請求項39記載の調 製物。 41.前記活性成分がオキシブチニンを含み、かつ、前記担体がゲランガムを含む 請求項18記載の調製物。 42.更にオレイン酸を含む請求項41記載の調整物。 43.更に大豆油を含む請求項41記載の調製物。 44.更にポリエチレンオキシドを含む請求項42記載の調製物。 45.前記ポリエチレンオキシドが約7×106の分子量を有する請求項44記載 の調製物。 46.尿道カテーテル法により、薬学的活性成分及び該活性成分の膀胱内の持続デ リバリーを可能にし、かつ生体分解後に尿路を通して排泄可能である生分解性 の薬学的に許容可能な担体を含む生分解性の徐放性調製物を患者の膀胱内に置 く工程を含む、失禁物の処理法。 47.尿道カテーテル法により、薬学的活性成分及び該活性成分の膀胱内の持続デ リバリーを可能にし、かつ生体分解後に尿路を通して排泄可能である生分解性 の薬学的に許容可能な担体を含む生分解性の徐放性調製物を患者の膀胱内に置 く工程を含む、間質性膀胱炎の治療法。 48.尿道カテーテル法により、薬学的活性成分及び該活性成分の膀胱内の持続デ リバリーを可能にし、かつ生体分解後に尿路を通して排泄可能である生分解性 の薬学的に許容可能な担体を含む生分解性の徐放性調製物を患者の膀胱内に置 く工程を含む、癌の治療法。 49.尿道カテーテル法により、薬学的活性成分及び該活性成分の膀胱内の持続デ リバリーを可能にし、かつ生体分解後に尿路を通して排泄可能である生分解性 の薬学的に許容可能な担体を含む生分解性の徐放性調製物を患者の膀胱内に置 く工程を含む、炎症の治療法。 50.尿道カテーテル法により、薬学的活性成分及び該活性成分の膀胱内の持続デ リバリーを可能にし、かつ生体分解後に尿路を通して排泄可能である生分解性 の薬学的に許容可能な担体を含む生分解性の徐放性調製物を患者の膀胱内に置 く工程を含む、感染症の治療法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83324797A | 1997-04-03 | 1997-04-03 | |
US08/833,247 | 1997-04-03 | ||
PCT/US1998/006445 WO1998043555A1 (en) | 1997-04-03 | 1998-04-02 | Intravesical drug delivery system |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001519787A true JP2001519787A (ja) | 2001-10-23 |
JP2001519787A5 JP2001519787A5 (ja) | 2005-11-24 |
Family
ID=25263865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54197098A Ceased JP2001519787A (ja) | 1997-04-03 | 1998-04-02 | 膀胱内ドラッグデリバリーシステム |
Country Status (10)
Country | Link |
---|---|
US (3) | US6039967A (ja) |
EP (1) | EP0971641A4 (ja) |
JP (1) | JP2001519787A (ja) |
KR (1) | KR20010006027A (ja) |
AU (1) | AU6876498A (ja) |
CA (1) | CA2285591A1 (ja) |
DE (1) | DE19882286T1 (ja) |
GB (1) | GB2338414B (ja) |
NO (1) | NO994837L (ja) |
WO (1) | WO1998043555A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006013851A1 (ja) * | 2004-08-03 | 2006-02-09 | Nippon Shinyaku Co., Ltd. | 体孔内用デバイス及び持続性製剤 |
JP2006506385A (ja) * | 2002-10-22 | 2006-02-23 | ザ バイオメリックス コーポレーション | 治療剤を小嚢内デリバリーするための方法およびシステム |
JP2009504271A (ja) * | 2005-08-11 | 2009-02-05 | マサチューセッツ・インスティテュート・オブ・テクノロジー | 膀胱内薬物送達デバイスおよび方法 |
JP2022531163A (ja) * | 2019-04-30 | 2022-07-06 | トリゴン ファーマ リミテッド | 膀胱への薬剤滴下投与用の製剤および方法と、膀胱疾患の治療 |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6214331B1 (en) * | 1995-06-06 | 2001-04-10 | C. R. Bard, Inc. | Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained |
AR018321A1 (es) * | 1998-03-26 | 2001-11-14 | Alza Corp | Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada. |
US6623751B2 (en) * | 1998-07-30 | 2003-09-23 | L'oreal S.A. | Cosmetic, pharmaceutical, or dermatological patch |
US6293923B1 (en) | 1999-03-15 | 2001-09-25 | Innoventions, Inc. | Intravesicular balloon |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
EP1949890A3 (en) * | 1999-06-04 | 2011-05-18 | ALZA Corporation | Implantable gel compositions and method of manufacture |
HUP0201626A3 (en) * | 1999-06-04 | 2004-05-28 | Alza Corp Mountain View | Implantable gel compositions and method of manufacture |
US6527718B1 (en) | 1999-08-20 | 2003-03-04 | Brian G Connor | Ultrasound system for continuous imaging and delivery of an encapsulated agent |
US6740039B1 (en) | 1999-08-20 | 2004-05-25 | Koninklijke Philips Electronics N.V. | Methods and apparatus for displaying information relating to delivery and activation of a therapeutic agent using ultrasound energy |
MX342305B (es) * | 2000-04-26 | 2016-09-23 | Watson Pharmaceuticals Inc * | Minimizacion de experiencias adversas asociadas con la terapia con oxibutinina. |
US7029694B2 (en) * | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US20030124177A1 (en) * | 2000-04-26 | 2003-07-03 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US6398718B1 (en) | 2000-06-15 | 2002-06-04 | Innoventions, Inc. | Intravesicular device |
US6545046B2 (en) | 2000-08-30 | 2003-04-08 | Theramax Inc. | Method for enhanced delivery of oxybutynin and compositions thereof |
US6699665B1 (en) * | 2000-11-08 | 2004-03-02 | Surface Logix, Inc. | Multiple array system for integrating bioarrays |
US6558312B2 (en) | 2001-03-13 | 2003-05-06 | Clemson University | Intraurethral device for incontinence |
WO2002071922A2 (en) * | 2001-03-13 | 2002-09-19 | Clemson University | Intraurethral device for treating or detecting various diseases or infections of the urinary system |
KR100426636B1 (ko) * | 2001-05-18 | 2004-04-08 | 한국과학기술연구원 | 주사 가능한 젤 상의 조성물 및 그의 제조방법 |
US6702744B2 (en) * | 2001-06-20 | 2004-03-09 | Advanced Cardiovascular Systems, Inc. | Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery |
US8110217B2 (en) * | 2001-08-13 | 2012-02-07 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
US7063860B2 (en) * | 2001-08-13 | 2006-06-20 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
US6878693B2 (en) | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
US20050233003A1 (en) * | 2001-09-28 | 2005-10-20 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid |
US20050227911A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
US6893431B2 (en) * | 2001-10-15 | 2005-05-17 | Scimed Life Systems, Inc. | Medical device for delivering patches |
AU2002350115A1 (en) * | 2001-11-01 | 2003-05-12 | Spectrum Pharmaceuticals, Inc. | Medical compositions for intravesical treatment of bladder cancer |
US8563592B2 (en) | 2001-11-01 | 2013-10-22 | Spectrum Pharmaceuticals, Inc. | Bladder cancer treatment and methods |
US7700851B2 (en) * | 2001-11-13 | 2010-04-20 | U.S. Smokeless Tobacco Company | Tobacco nicotine demethylase genomic clone and uses thereof |
US8608661B1 (en) | 2001-11-30 | 2013-12-17 | Advanced Cardiovascular Systems, Inc. | Method for intravascular delivery of a treatment agent beyond a blood vessel wall |
US8685427B2 (en) | 2002-07-31 | 2014-04-01 | Boston Scientific Scimed, Inc. | Controlled drug delivery |
US8133501B2 (en) * | 2002-02-08 | 2012-03-13 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices for controlled drug delivery |
US7361368B2 (en) | 2002-06-28 | 2008-04-22 | Advanced Cardiovascular Systems, Inc. | Device and method for combining a treatment agent and a gel |
US8920826B2 (en) * | 2002-07-31 | 2014-12-30 | Boston Scientific Scimed, Inc. | Medical imaging reference devices |
US7149874B2 (en) * | 2002-08-16 | 2006-12-12 | Micron Technology, Inc. | Memory hub bypass circuit and method |
US7597903B2 (en) * | 2002-12-02 | 2009-10-06 | Shenkar College Of Engineering And Design | Method and composition for producing catheters with antibacterial property |
US20060058777A1 (en) * | 2002-12-11 | 2006-03-16 | Pia Norup Nielsen | Urinary catheter device with a pharmaceutically active composition |
JP2004246317A (ja) * | 2002-12-20 | 2004-09-02 | Hitachi Ltd | 冷陰極型フラットパネルディスプレイ |
EP3103422A1 (en) | 2003-03-14 | 2016-12-14 | Intersect ENT, Inc. | Sinus delivery of sustained release therapeutics |
US8821473B2 (en) * | 2003-04-15 | 2014-09-02 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
US7641643B2 (en) * | 2003-04-15 | 2010-01-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
US8038991B1 (en) | 2003-04-15 | 2011-10-18 | Abbott Cardiovascular Systems Inc. | High-viscosity hyaluronic acid compositions to treat myocardial conditions |
BRPI0410324A (pt) | 2003-05-15 | 2006-05-23 | Biomerix Corp | dispositivo implantável, processos de liofilização para produção de matriz elastomérica possuindo uma estrutura reticulada, de polimerização para a preparação de matriz elastomérica reticulada e de preparação de dispositivo implantável elastomérico de compósito reticulado, e, método para tratamento de uma desordem ortopédica |
US20040249364A1 (en) * | 2003-06-03 | 2004-12-09 | Ilya Kaploun | Device and method for dispensing medication to tissue lining a body cavity |
CA2533165A1 (en) * | 2003-07-21 | 2005-01-27 | Bio-Dar Ltd. | Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention |
NZ528648A (en) | 2003-10-02 | 2005-08-26 | Agres Ltd | Altering animal waste composition |
US20050175709A1 (en) * | 2003-12-11 | 2005-08-11 | Baty Ace M.Iii | Therapeutic microparticles |
US7763077B2 (en) | 2003-12-24 | 2010-07-27 | Biomerix Corporation | Repair of spinal annular defects and annulo-nucleoplasty regeneration |
US8361490B2 (en) | 2004-09-16 | 2013-01-29 | Theracoat Ltd. | Biocompatible drug delivery apparatus and methods |
US7854944B2 (en) | 2004-12-17 | 2010-12-21 | Advanced Cardiovascular Systems, Inc. | Tissue regeneration |
WO2006107957A2 (en) | 2005-04-04 | 2006-10-12 | Sinexus, Inc. | Device and methods for treating paranasal sinus conditions |
US8828433B2 (en) | 2005-04-19 | 2014-09-09 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
US8303972B2 (en) * | 2005-04-19 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
US9539410B2 (en) | 2005-04-19 | 2017-01-10 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating post-cardial infarction damage |
US8187621B2 (en) | 2005-04-19 | 2012-05-29 | Advanced Cardiovascular Systems, Inc. | Methods and compositions for treating post-myocardial infarction damage |
US20080125745A1 (en) | 2005-04-19 | 2008-05-29 | Shubhayu Basu | Methods and compositions for treating post-cardial infarction damage |
ATE540996T1 (de) | 2005-06-06 | 2012-01-15 | Univ British Columbia | Polymerbasierter serumalbumin-ersatzstoff |
US7732190B2 (en) * | 2006-07-31 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
US9242005B1 (en) | 2006-08-21 | 2016-01-26 | Abbott Cardiovascular Systems Inc. | Pro-healing agent formulation compositions, methods and treatments |
WO2008035172A2 (en) * | 2006-09-18 | 2008-03-27 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions containing desmopressin |
US8741326B2 (en) * | 2006-11-17 | 2014-06-03 | Abbott Cardiovascular Systems Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
US9005672B2 (en) * | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
US8192760B2 (en) * | 2006-12-04 | 2012-06-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating tissue using silk proteins |
US8702591B2 (en) * | 2007-01-12 | 2014-04-22 | Olympus Medical Systems Corp. | Capsule medical apparatus |
US20080161639A1 (en) * | 2006-12-28 | 2008-07-03 | Olympus Medical Systems Corporation | Capsule medical apparatus and body-cavity observation method |
DE102007003765A1 (de) * | 2007-01-19 | 2008-07-24 | Farco-Pharma Gmbh | Pharmazeutische Zusammensetzung zur Behandlung von Inkontinenz |
ES2481454T3 (es) * | 2007-12-11 | 2014-07-30 | Massachusetts Institute Of Technology | Dispositivo implantable de administración de fármacos |
US8585730B2 (en) | 2007-12-18 | 2013-11-19 | Intersect Ent, Inc. | Self-expanding devices and methods therefor |
WO2010014834A1 (en) | 2008-08-01 | 2010-02-04 | Sinexus, Inc. | Methods and devices for crimping self-expanding devices |
EP2328628A2 (en) * | 2008-08-09 | 2011-06-08 | Massachusetts Institute of Technology | Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues |
US20100291182A1 (en) * | 2009-01-21 | 2010-11-18 | Arsenal Medical, Inc. | Drug-Loaded Fibers |
US8974368B2 (en) | 2009-04-28 | 2015-03-10 | Ams Research Corporation | Pelvic tissue support devices |
CA3031836A1 (en) | 2009-05-05 | 2010-11-11 | Board Of Regents, The University Of Texas System | Formulations of volatile anesthetics for reducing inflammation |
CA3001814C (en) | 2009-05-15 | 2020-12-22 | Intersect Ent, Inc. | Expandable devices and methods therefor |
CN101724163B (zh) * | 2009-06-23 | 2011-09-07 | 河南科技大学 | 一种壳聚糖衍生物复合微球及其制备方法和应用 |
EP2445571B1 (en) * | 2009-06-26 | 2012-11-21 | Taris Biomedical, Inc. | Solid drug tablets for implantable drug delivery devices |
DE102009035586A1 (de) | 2009-07-31 | 2011-02-03 | Fresenius Kabi Deutschland Gmbh | Intravesikale Instillationslösungen zur Behandlung von Blasenkrebs |
US9044580B2 (en) | 2009-08-24 | 2015-06-02 | Arsenal Medical, Inc. | In-situ forming foams with outer layer |
US10420862B2 (en) | 2009-08-24 | 2019-09-24 | Aresenal AAA, LLC. | In-situ forming foams for treatment of aneurysms |
US9173817B2 (en) | 2009-08-24 | 2015-11-03 | Arsenal Medical, Inc. | In situ forming hemostatic foam implants |
US20110202016A1 (en) * | 2009-08-24 | 2011-08-18 | Arsenal Medical, Inc. | Systems and methods relating to polymer foams |
US9017312B2 (en) * | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
AU2015201123B2 (en) * | 2009-12-17 | 2016-04-21 | Taris Biomedical Llc | Implantable device with intravesical tolerability and methods of treatment |
PL2512581T3 (pl) * | 2009-12-17 | 2021-11-02 | Taris Biomedical Llc | Wszczepiane urządzenie z tolerancją wewnątrzpęcherzową |
ES2732150T3 (es) | 2010-01-20 | 2019-11-20 | Urogen Pharma Ltd | Material y método para tratar cavidades internas |
EP2542613A4 (en) | 2010-03-01 | 2013-12-11 | Univ British Columbia | DERIVATED HYPER BRANCHED POLYGLYCEROLS |
ES2822118T3 (es) | 2010-08-05 | 2021-04-29 | Taris Biomedical Llc | Dispositivos de administración de fármacos implantables para sitios genitourinarios |
WO2012048114A1 (en) * | 2010-10-06 | 2012-04-12 | Taris Biomedical, Inc. | Time-selective bioresorbable or collapsible drug delivery systems and methods |
RU2620032C2 (ru) | 2011-01-10 | 2017-05-22 | Аллерган, Инк. | Схема приема лидокаина для применения в продолжительном лечении боли в мочевом пузыре и раздражения при мочеиспускании |
US9034240B2 (en) | 2011-01-31 | 2015-05-19 | Arsenal Medical, Inc. | Electrospinning process for fiber manufacture |
US9194058B2 (en) | 2011-01-31 | 2015-11-24 | Arsenal Medical, Inc. | Electrospinning process for manufacture of multi-layered structures |
US8968626B2 (en) | 2011-01-31 | 2015-03-03 | Arsenal Medical, Inc. | Electrospinning process for manufacture of multi-layered structures |
US9107816B2 (en) | 2011-02-04 | 2015-08-18 | Taris Biomedical Llc | Implantable device for controlled dissolution and diffusion of low solubility drug |
US8476221B2 (en) | 2011-03-18 | 2013-07-02 | Halimed Pharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders |
EP2734187B1 (en) | 2011-07-20 | 2018-09-05 | UroGen Pharma Ltd. | Materials and method for treating internal body cavities |
EP2771320B1 (en) | 2011-10-24 | 2016-06-22 | Endo Pharmaceuticals Inc. | Cyclohexylamines |
US8993831B2 (en) | 2011-11-01 | 2015-03-31 | Arsenal Medical, Inc. | Foam and delivery system for treatment of postpartum hemorrhage |
US10857336B2 (en) | 2012-05-19 | 2020-12-08 | Taris Biomedical Llc | Implantable urological device with improved retrieval feature |
EP3636227B1 (en) | 2013-03-14 | 2024-08-28 | Intersect ENT, Inc. | Systems and devices for treating a sinus condition |
SG10201708522SA (en) | 2013-03-15 | 2017-12-28 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
ES2956840T3 (es) | 2013-08-19 | 2023-12-29 | Taris Biomedical Llc | Dispositivos de administración de fármacos de múltiples unidades |
WO2015095128A1 (en) | 2013-12-16 | 2015-06-25 | Asana Biosciences, Llc | P2x3 and/or p2x2/3 compounds and methods |
CN103861091B (zh) * | 2014-03-20 | 2016-04-27 | 辽宁亿灵科创生物医药科技有限公司 | 治疗膀胱炎的药物组合物 |
CN106456951B (zh) | 2014-06-26 | 2021-11-05 | 塔里斯生物医药公司 | 包含弹性聚合物-药物基质系统的膀胱内药物递送装置及方法 |
CZ308594B6 (cs) * | 2014-09-29 | 2020-12-23 | VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. | Mukoadhezivní nosiče částic, způsob přípravy a použití |
AU2016209105B2 (en) | 2015-01-22 | 2020-05-14 | Intersect Ent, Inc. | Drug-coated balloon |
WO2016172704A1 (en) | 2015-04-23 | 2016-10-27 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
CA3037748A1 (en) | 2016-09-30 | 2018-04-05 | Asana Biosciences, Llc | P2x3 and/or p2x2/3 compounds and methods |
IT201700104446A1 (it) | 2017-09-19 | 2019-03-19 | Lo Li Pharma Srl | Compositions, uses and methods for treatment of infertility and subfertility |
CA3085612A1 (en) | 2017-12-22 | 2019-06-27 | Lo.Li. Pharma International S.R.L. | Treatment of fibrosis with inositol |
EP3856143A4 (en) * | 2018-09-27 | 2022-07-06 | Watershed Medical, Inc. | DEVICE AND METHOD FOR TREATING INFECTIONS |
US20220107320A1 (en) | 2019-02-15 | 2022-04-07 | Incelldx, Inc. | Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein |
IT201900003843A1 (it) | 2019-03-15 | 2020-09-15 | Lo Li Pharma Srl | Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG) |
US20210100950A1 (en) | 2019-10-02 | 2021-04-08 | Watershed Medical, Inc. | Device and method for improving retention of a therapy in the bladder |
WO2023205703A2 (en) * | 2022-04-19 | 2023-10-26 | Watershed Medical, Inc. | Formulation for treating urinary system disorders |
IT202200013867A1 (it) | 2022-06-30 | 2023-12-30 | Lo Li Pharma Srl | Composizione per il trattamento dell’ infezione da papilloma virus (hpv) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2961374A (en) * | 1950-10-14 | 1960-11-22 | Lieb Hans | Injectable pharmaceutical preparation, and a method of making same |
JPS51140582A (en) * | 1975-05-30 | 1976-12-03 | Nec Corp | Semiconductor resistance element |
US4774091A (en) * | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
FR2588189B1 (fr) * | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
US4871542A (en) * | 1987-04-30 | 1989-10-03 | Ferring Service Center, N.V. | Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract |
FR2657018A1 (fr) * | 1990-01-12 | 1991-07-19 | Merck Sharp & Dohme | Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation. |
AU7991191A (en) * | 1990-05-23 | 1991-12-10 | Southwest Research Institute | Filament system for delivering a medicament and method |
EP0572932B1 (en) * | 1992-06-02 | 2000-09-13 | C.R. Bard, Inc. | Method and implant device for long term delivery of drugs |
-
1998
- 1998-04-02 JP JP54197098A patent/JP2001519787A/ja not_active Ceased
- 1998-04-02 AU AU68764/98A patent/AU6876498A/en not_active Abandoned
- 1998-04-02 US US09/054,154 patent/US6039967A/en not_active Expired - Fee Related
- 1998-04-02 WO PCT/US1998/006445 patent/WO1998043555A1/en not_active Application Discontinuation
- 1998-04-02 CA CA002285591A patent/CA2285591A1/en not_active Abandoned
- 1998-04-02 DE DE19882286T patent/DE19882286T1/de not_active Withdrawn
- 1998-04-02 GB GB9923410A patent/GB2338414B/en not_active Expired - Fee Related
- 1998-04-02 KR KR1019997009105A patent/KR20010006027A/ko not_active Application Discontinuation
- 1998-04-02 EP EP98914404A patent/EP0971641A4/en not_active Withdrawn
-
1999
- 1999-10-04 NO NO994837A patent/NO994837L/no not_active Application Discontinuation
-
2000
- 2000-03-14 US US09/525,609 patent/US6207180B1/en not_active Expired - Fee Related
-
2001
- 2001-03-27 US US09/819,117 patent/US6524608B2/en not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006506385A (ja) * | 2002-10-22 | 2006-02-23 | ザ バイオメリックス コーポレーション | 治療剤を小嚢内デリバリーするための方法およびシステム |
WO2006013851A1 (ja) * | 2004-08-03 | 2006-02-09 | Nippon Shinyaku Co., Ltd. | 体孔内用デバイス及び持続性製剤 |
JP2009504271A (ja) * | 2005-08-11 | 2009-02-05 | マサチューセッツ・インスティテュート・オブ・テクノロジー | 膀胱内薬物送達デバイスおよび方法 |
JP2022531163A (ja) * | 2019-04-30 | 2022-07-06 | トリゴン ファーマ リミテッド | 膀胱への薬剤滴下投与用の製剤および方法と、膀胱疾患の治療 |
JP7350372B2 (ja) | 2019-04-30 | 2023-09-26 | トリゴン ファーマ リミテッド | 膀胱への薬剤滴下投与用の製剤および方法と、膀胱疾患の治療 |
Also Published As
Publication number | Publication date |
---|---|
GB9923410D0 (en) | 1999-12-08 |
DE19882286T1 (de) | 2000-04-27 |
NO994837D0 (no) | 1999-10-04 |
CA2285591A1 (en) | 1998-10-08 |
GB2338414A (en) | 1999-12-22 |
US6524608B2 (en) | 2003-02-25 |
GB2338414B (en) | 2001-12-19 |
KR20010006027A (ko) | 2001-01-15 |
EP0971641A4 (en) | 2003-08-13 |
US20010019719A1 (en) | 2001-09-06 |
EP0971641A1 (en) | 2000-01-19 |
AU6876498A (en) | 1998-10-22 |
US6039967A (en) | 2000-03-21 |
US6207180B1 (en) | 2001-03-27 |
NO994837L (no) | 1999-11-10 |
WO1998043555A1 (en) | 1998-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001519787A (ja) | 膀胱内ドラッグデリバリーシステム | |
AU762677B2 (en) | Prolonged release bioadhesive vaginal gel dosage form | |
EP1263416B1 (en) | Compressed microparticles for dry injection | |
JP3941878B2 (ja) | 生物分解性放出制御溶融紡糸デリバリーシステム | |
JP3263399B2 (ja) | 局所投与型生分解性徐放型歯周炎用薬剤組成物及びその製造方法 | |
US6488952B1 (en) | Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system | |
JPH10502673A (ja) | 持続性の局所麻酔を施すための製剤および方法 | |
JP2009509982A (ja) | 内耳疾患を治療するための医薬品組成物 | |
WO1989009066A1 (en) | Controlled release composition | |
JP2002521347A (ja) | 陰イオン多糖を含む徐放製剤 | |
DE212011100034U1 (de) | Material zur Behandlung von inneren Hohlräumen | |
JPH07179361A (ja) | 歯周病処置用複合物質 | |
JP2007503394A (ja) | 動物に薬物投与するための可食性フィルム | |
JP2001515456A (ja) | 口腔の苦痛状態を治療するための経口投与および方法 | |
JP2002524494A (ja) | 一時的および空間的制御を供する経口で投与された制御薬剤送出系 | |
AU2005261682A1 (en) | A delivery system | |
JPWO2007102447A1 (ja) | 付着型マイクロカプセル | |
JP2016028066A (ja) | 制御放出分配デバイス | |
P Venkatesh et al. | In situ gels based drug delivery systems | |
Askari et al. | Ionotropically cross-linked Gellan gum-based matrices in drug delivery | |
EP3222270A1 (en) | Compositions for mucosal adhesion and uses thereof | |
Sheu | Chia-Yu Su1, Hsiu-O Ho1, Ying-Chen Chen1, Yu-Ting Yu1, Der-Zen Liu2, Fang-Ching Chao1 & | |
Samad et al. | 20 Microsphere |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050404 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081209 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090309 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090427 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090629 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090804 |